Lundberg, Ingrid E. http://orcid.org/0000-0002-6068-9212
Fujimoto, Manabu http://orcid.org/0000-0002-3062-4872
Vencovsky, Jiri http://orcid.org/0000-0002-0851-0713
Aggarwal, Rohit
Holmqvist, Marie http://orcid.org/0000-0001-8996-5260
Christopher-Stine, Lisa http://orcid.org/0000-0002-7150-7306
Mammen, Andrew L. http://orcid.org/0000-0003-3732-3252
Miller, Frederick W.
Article History
Accepted: 19 October 2021
First Online: 2 December 2021
Competing interests
: I.E.L. has received research funding from AstraZeneca and Bristol Myers Squibb, has served on advisory boards for Corbus Pharmaceutical, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezaar, Orphazyme, Janssen, and Pfizer and has stock shares in Roche and Novartis. M.F. has received research funding and speakers fee from Abbvie, Amgen, Eli Lilly, Japan Blood Product Organization, Kyowa-Kirin, Maruho, Novartis, Sanofi and Taiho. J.V. has been on Speakers Bureaus of Abbvie, Biogen, MSD, Pfizer, Roche, Sanofi, and UCB and has consulted for Abbvie, Argenx, Boehringer, Eli Lilly and Octapharma. R.A. receives research funding from BMS, Mallinckrodt, Genentech, and Pfizer and has served as a consultant for BMS, Mallinckrodt, Pfizer, Orphazyme, Octapharma, Kyverna, Kezar, Janssen, Csl Behring, Corbus, Boehringer-Ingelheim, AstraZeneca, Argenx, Alexion, Q32 and Abbvie. L.C-S. has research support from Pfizer, Corbus, and Kezar and has served on advisory boards for UCB (not myositis related), Janssen, Boehringer-Ingelheim, Mallinckrodt, Serono, Argenx, Roivant and Dysimmune Disease Foundation (DDF), and received compensation for consultancy work from Guidepoint and Allogene. She is also a patent holder on an assay for anti-HMGCR auto-antibodies for which she received royalty payments from Inova Diagnostics. A.L.M. is a patent holder on an assay for anti-HMGCR auto-antibodies but does not receive any royalties. The other authors declare no competing interests.